Considering that some of milk beverages contain various types of additives like coffee or chicory as healthier option, the aim of this research is to examine if milk beverages could serve as additional source of asparagine, which could support the body to meet needs for dispensable amino acids. For the purpose of asparagine content determination, the choice fell on the method based upon redox reaction of asparagine with potassium permanganate, KMnO4. The values show that the concentration of asparagine in the milk samples with chicory as an additive is higher (0.98 – 1.07 mg/l), in comparison with milk samples without additives where lower asparagine concentrations (0.26 - 0.40 mg/l) can be observed. Taking into account the above presented results it can be concluded that in addition to the specified amount of amino acids the consumer receives through milk, certain amounts of dispensable amino acids can be entered through supplements, as it is the case with asparagine from coffee or chicory.

No abstract

No abstract

Abstract:The main purpose of this research study is the determination of volatile flavoring substance acetaldehyde in some fermented, industrially manufactured dairy products, offered on the Bitola's market and the comparison with acetaldehyde quantities measured in fermented dairy products produced in laboratory conditions. Six samples of fermented dairy products (yoghurt and sour milk) were purchased from the local supermarkets and four samples were "homemade" manufactured in laboratory conditions. Results of the acetaldehyde quantities in different fermented dairy products were obtained through the observation of acetaldehyde values successively in a two week period and, in order to confirm the mutual correlation of variables, i.e. of the absorbance and concentration, calibration curve was created. The highest acetaldehyde quantities in all fermented dairy samples were measured on the first day of this research study, while after the fifteenth day of examination acetaldehyde concentration in each sample was equal to zero. Undoubtedly, certain conditions like pH, temperature, strain ratio, etc. need to be met.UDC classification: 637; DOI: http://dx

Background. During the last decade, significant improvement was made in systemic therapy of pancreatic adenocarcinoma (PAC). The impact of this progress in everyday clinical practice has not been fully described yet. The aim of the study was to investigate the pattern followed by Greek Medical Oncologists regarding the treatment of patients with PAC. Methods. This observational, noninterventional multicenter study recorded clinical data from the files of 200 active patients (alive and under treatment or follow-up) for a two-year period (November 2015 until November 2017) from 20 oncology centers around Greece. Results. In total, 51 (25.5%) patients underwent radical surgical resection of PAC, and 40 (78.4%) of them received adjuvant and 1 (2.0%) neoadjuvant chemotherapy. The median time to recurrence was 7.9 months, and median overall survival (OS), 20.2 months. First-line chemotherapy was administered to 193 (96.5%) patients. The majority of patients were treated with the combination of nab-paclitaxel-gemcitabine (NPG), 5-fluorouracil, leucovorin, irinotecan, oxaliplatin (FOLFIRINOX), or gemcitabine monotherapy. Of them, 39.5% responded to the treatment. Median OS and PFS were 14.1 months and 7.0 months, respectively. Second-line treatment was administered to 112 patients. The majority received NPG, FOLFIRINOX/capecitabine, oxaliplatin, irinotecan (CAPOXIRI), or 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX)/capecitabine, oxaliplatin (CAPOX). Median OS with second-line treatment was 8.6 months, and median PFS, 5.5 months. The most common chemotherapy sequences were NPG as first-line followed by FOLFIRINOX/CAPOXIRI as second-line, NPG followed by FOLFOX/CAPOX, NPG followed by other regimens, and FOLFIRINOX/CAPOXIRI followed by NPG. Conclusion. This study described the significant improvement in prognosis of PAC patients receiving palliative chemotherapy and the relatively high rate of receipt of second-line chemotherapy, according to real-world data. However, due to the nonrandomized nature of the study, any comparison between different chemotherapy regimens should be regarded with caution.